scholarly journals Ischemia and Reperfusion Injury in Kidney Transplantation: Relevant Mechanisms in Injury and Repair

2020 ◽  
Vol 9 (1) ◽  
pp. 253 ◽  
Author(s):  
Gertrude J. Nieuwenhuijs-Moeke ◽  
Søren E. Pischke ◽  
Stefan P. Berger ◽  
Jan Stephan F. Sanders ◽  
Robert A. Pol ◽  
...  

Ischemia and reperfusion injury (IRI) is a complex pathophysiological phenomenon, inevitable in kidney transplantation and one of the most important mechanisms for non- or delayed function immediately after transplantation. Long term, it is associated with acute rejection and chronic graft dysfunction due to interstitial fibrosis and tubular atrophy. Recently, more insight has been gained in the underlying molecular pathways and signalling cascades involved, which opens the door to new therapeutic opportunities aiming to reduce IRI and improve graft survival. This review systemically discusses the specific molecular pathways involved in the pathophysiology of IRI and highlights new therapeutic strategies targeting these pathways.

2022 ◽  
Vol 8 ◽  
Author(s):  
L. Leonie van Leeuwen ◽  
Henri G. D. Leuvenink ◽  
Peter Olinga ◽  
Mitchel J. R. Ruigrok

Great efforts have been made toward addressing the demand for donor kidneys. One of the most promising approaches is to use kidneys from donation after circulatory death donors. These kidneys, however, suffer from more severe ischemia and reperfusion injury than those obtained via donation after brain death and are thus more prone to develop interstitial fibrosis and tubular atrophy. Even though machine perfusion is increasingly used to reduce ischemia and reperfusion injury, there are no effective treatments available to ameliorate interstitial fibrosis and tubular atrophy, forcing patients to resume dialysis, undergo re-transplantation, or suffer from premature death. Safe and effective anti-fibrotic therapies are therefore greatly desired. We propose a new therapeutic approach in which machine perfusion solutions are supplemented with anti-fibrotic compounds. This allows the use of higher concentrations than those used in humans whilst eliminating side effects in other organs. To the authors' knowledge, no one has reviewed whether such an approach could reduce interstitial fibrosis and tubular atrophy; we therefore set out to explore its merit. In this review, we first provide background information on ischemia and reperfusion injury as well as interstitial fibrosis and tubular atrophy, after which we describe currently available approaches for preserving donor kidneys. We then present an evaluation of selected compounds. To identify promising compounds, we analyzed publications describing the effects of anti-fibrotic molecules in precision-cut kidneys slices, which are viable explants that can be cultured ex vivo for up to a few days whilst retaining functional and structural features. LY2109761, galunisertib, imatinib, nintedanib, and butaprost were shown to exert anti-fibrotic effects in slices within a relatively short timeframe (<48 h) and are therefore considered to be excellent candidates for follow-up ex vivo machine perfusion studies.


2021 ◽  
Vol 22 (4) ◽  
pp. 2157
Author(s):  
Anila Duni ◽  
Vassilios Liakopoulos ◽  
Vasileios Koutlas ◽  
Charalampos Pappas ◽  
Michalis Mitsis ◽  
...  

The damage of the endothelial glycocalyx as a consequence of ischemia and/or reperfusion injury (IRI) following kidney transplantation has come at the spotlight of research due to potential associations with delayed graft function, acute rejection as well as long-term allograft dysfunction. The disintegration of the endothelial glycocalyx induced by IRI is the crucial event which exposes the denuded endothelial cells to further inflammatory and oxidative damage. The aim of our review is to present the currently available data regarding complex links between shedding of the glycocalyx components, like syndecan-1, hyaluronan, heparan sulphate, and CD44 with the activation of intricate immune system responses, including toll-like receptors, cytokines and pro-inflammatory transcription factors. Evidence on modes of protection of the endothelial glycocalyx and subsequently maintenance of endothelial permeability as well as novel nephroprotective molecules such as sphingosine-1 phosphate (S1P), are also depicted. Although advances in technology are making the visualization and the analysis of the endothelial glycocalyx possible, currently available evidence is mostly experimental. Ongoing progress in understanding the complex impact of IRI on the endothelial glycocalyx, opens up a new era of research in the field of organ transplantation and clinical studies are of utmost importance for the future.


2011 ◽  
Vol 43 (1) ◽  
pp. 70-73 ◽  
Author(s):  
L.R. Requião-Moura ◽  
M. de Souza Durão ◽  
E.J. Tonato ◽  
A.C. Carvalho Matos ◽  
K.S. Ozaki ◽  
...  

2004 ◽  
Vol 66 (2) ◽  
pp. 523-527 ◽  
Author(s):  
Faikah Gueler ◽  
Winfried Gwinner ◽  
Anke Schwarz ◽  
Hermann Haller

2015 ◽  
Vol 13 (1) ◽  
pp. 129-135 ◽  
Author(s):  
Lúcio Roberto Requião-Moura ◽  
Marcelino de Souza Durão Junior ◽  
Ana Cristina Carvalho de Matos ◽  
Alvaro Pacheco-Silva

Ischemia and reperfusion injury is an inevitable event in renal transplantation. The most important consequences are delayed graft function, longer length of stay, higher hospital costs, high risk of acute rejection, and negative impact of long-term follow-up. Currently, many factors are involved in their pathophysiology and could be classified into two different paradigms for education purposes: hemodynamic and immune. The hemodynamic paradigm is described as the reduction of oxygen delivery due to blood flow interruption, involving many hormone systems, and oxygen-free radicals produced after reperfusion. The immune paradigm has been recently described and involves immune system cells, especially T cells, with a central role in this injury. According to these concepts, new strategies to prevent ischemia and reperfusion injury have been studied, particularly the more physiological forms of storing the kidney, such as the pump machine and the use of antilymphocyte antibody therapy before reperfusion. Pump machine perfusion reduces delayed graft function prevalence and length of stay at hospital, and increases long-term graft survival. The use of antilymphocyte antibody therapy before reperfusion, such as Thymoglobulin™, can reduce the prevalence of delayed graft function and chronic graft dysfunction.


2013 ◽  
Vol 33 (3) ◽  
pp. 879-887 ◽  
Author(s):  
Nurettin AYDOĞDU ◽  
Mehmet KANTER ◽  
Ömer YALÇIN ◽  
Ebru TAŞTEKİN ◽  
Kadir KAYMAK

PLoS ONE ◽  
2015 ◽  
Vol 10 (8) ◽  
pp. e0136145 ◽  
Author(s):  
Marina Gabriela Monteiro Carvalho Mori da Cunha ◽  
Silvia Zia ◽  
Fanny Oliveira Arcolino ◽  
Marianne Sylvia Carlon ◽  
Diego Vilibaldo Beckmann ◽  
...  

2021 ◽  
Vol 2 (2) ◽  
pp. 191-207
Author(s):  
Davide Loizzo ◽  
Nicola Antonio di Meo ◽  
Mattia Rocco Peluso ◽  
Monica Rutigliano ◽  
Matteo Matera ◽  
...  

Ischemia reperfusion injury (IRI) is one of the most important mechanisms involved in delayed or reduced graft function after kidney transplantation. It is a complex pathophysiological process, followed by a pro-inflammatory response that enhances the immunogenicity of the graft and the risk of acute rejection. Many biologic processes are involved in its development, such as transcriptional reprogramming, the activation of apoptosis and cell death, endothelial dysfunction and the activation of the innate and adaptive immune response. Recent evidence has highlighted the importance of complement activation in IRI cascade, which expresses a pleiotropic action on tubular cells, on vascular cells (pericytes and endothelial cells) and on immune system cells. The effects of IRI in the long term lead to interstitial fibrosis and tubular atrophy, which contribute to chronic graft dysfunction and subsequently graft failure. Furthermore, several metabolic alterations occur upon IRI. Metabolomic analyses of IRI detected a “metabolic profile” of this process, in order to identify novel biomarkers that may potentially be useful for both early diagnosis and monitoring the therapeutic response. The aim of this review is to update the most relevant molecular mechanisms underlying IRI, and also to discuss potential therapeutic targets in future clinical practice.


Sign in / Sign up

Export Citation Format

Share Document